Physician profile
Mark P Robbins
NPI 1326058538
$99,203.56
in general payments reported to CMS, 2019-2025
13 companies · $95K in 2025
The $95K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $545 · 2021: $319 · 2022: $265 · 2023: $391 · 2024: $2,277 · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $95K · Food and Beverage: $1,653 · Travel and Lodging: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $95,000.00 |
| Food and Beverage | $1,653.30 |
| Travel and Lodging | $1,218.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $97,142.62 | 2023-2025 | |
| Organogenesis INC. | $631.96 | 2020-2023 | Puraply Antimicrobial, Puraply |
| Smith+Nephew, INC. | $343.07 | 2019-2025 | Renasys Go V2 Home, Grafix Pl, Renasys Touch |
| Kerecis Limited | $268.40 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $180.10 | 2020-2025 | Nuzyra |
| Abbvie INC. | $162.82 | 2021-2024 | Dalvance |
| Medtronic, INC. | $148.60 | 2024 | Intellis Adaptivestim |
| Janssen Scientific Affairs, LLC | $124.99 | 2021 | |
| Emd Serono, INC. | $99.50 | 2020 | |
| Hydrofera LLC | $47.07 | 2024 | Cutimed Sorbion |
| Next Science LLC | $24.08 | 2023 | Surgx, Xperience, Blastx |
| Reprise Biomedical, INC. | $15.68 | 2024 | Miro3d |
| Deroyal Industries, INC. | $14.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.